218 related articles for article (PubMed ID: 31755702)
1. Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Osko JD; Christianson DW
Biochemistry; 2019 Dec; 58(49):4912-4924. PubMed ID: 31755702
[TBL] [Abstract][Full Text] [Related]
2. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Osko JD; Christianson DW
Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
Hai Y; Christianson DW
Nat Chem Biol; 2016 Sep; 12(9):741-7. PubMed ID: 27454933
[TBL] [Abstract][Full Text] [Related]
4. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
5. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
6. Macrocyclic Octapeptide Binding and Inferences on Protein Substrate Binding to Histone Deacetylase 6.
Watson PR; Gupta S; Hosseinzadeh P; Brown BP; Baker D; Christianson DW
ACS Chem Biol; 2023 Apr; 18(4):959-968. PubMed ID: 37027789
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence Polarization-Based Competition Assays to Evaluate Histone Deacetylase 6 Inhibitors.
Ashraf QF; Quilates EJ; Olaoye OO; de Araujo ED; Gunning PT
Methods Mol Biol; 2023; 2589():481-492. PubMed ID: 36255644
[TBL] [Abstract][Full Text] [Related]
8. The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries.
Kutil Z; Skultetyova L; Rauh D; Meleshin M; Snajdr I; Novakova Z; Mikesova J; Pavlicek J; Hadzima M; Baranova P; Havlinova B; Majer P; Schutkowski M; Barinka C
FASEB J; 2019 Mar; 33(3):4035-4045. PubMed ID: 30496698
[TBL] [Abstract][Full Text] [Related]
9. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Sixto-López Y; Bello M; Correa-Basurto J
J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483
[TBL] [Abstract][Full Text] [Related]
10. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity.
Wu JY; Xiang S; Zhang M; Fang B; Huang H; Kwon OK; Zhao Y; Yang Z; Bai W; Bepler G; Zhang XM
J Biol Chem; 2018 Feb; 293(6):1976-1993. PubMed ID: 29259132
[TBL] [Abstract][Full Text] [Related]
14. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
16. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
Porter NJ; Wagner FF; Christianson DW
Biochemistry; 2018 Jul; 57(26):3916-3924. PubMed ID: 29775292
[TBL] [Abstract][Full Text] [Related]
17. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
18. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group?
Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H
J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561
[TBL] [Abstract][Full Text] [Related]
19. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
20. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]